Pegintron Market Report 2026

Pegintron Market Overview

• The Pegintron market growth in the historic period has been driven by long-standing clinical use in hepatitis treatment, established safety and efficacy data • Market expansion is supported by niche demand alongside newer antivirals, continued use in combination regimens • Growth Driver: Rising Prevalence Of Hepatitis C Is Driving The Growth Of The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Pegintron Market?

Pegintron is a brand name for peginterferon alfa-2b, a medication used to treat chronic hepatitis C and certain types of hepatitis B. It is a modified form of interferon that enhances its effectiveness by attaching a polyethylene glycol (PEG) molecule, which helps prolong its action in the body. Pegintron works by boosting the immune system's response to viral infections, aiming to reduce viral load and improve liver function. The main indication types of pegintron are chronic hepatitis C and chronic hepatitis B, chronic hepatitis C (CHC) is a liver disease caused by the hepatitis C virus (HCV) that persists over time, potentially leading to severe liver damage. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, catering to various end users, clinics, and homecare settings.

What Is The Pegintron Market Growth Forecast?

The growth in the forecast period can be attributed to niche demand alongside newer antivirals, continued use in combination regimens, increasing focus on personalized treatment selection, expansion of access in developing regions, ongoing clinical evaluation of interferon benefits. Major trends in the forecast period include increasing focus on pegylated interferon therapies, gradual decline in first-line usage, continued use in select patient profiles, emphasis on immune response modulation, optimization of dosing and administration.

Global Pegintron Market Segmentation

1) By Indication: Chronic Hepatitis C, Chronic Hepatitis B 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End User: Hospitals, Clinics, Homecare Settings

What Are The Drivers Of The Pegintron Market?

The rising prevalence of hepatitis C is expected to propel the growth of the pegintron market going forward. Hepatitis C refers to a viral infection caused by the hepatitis C virus (HCV) that primarily affects the liver. The rising prevalence of hepatitis C increases the burden on healthcare systems and drives the demand for effective diagnostic tools, antiviral treatments, and public health interventions. Pegintron, a pegylated interferon alfa-2b, helps treat hepatitis C by enhancing the immune system’s ability to fight the virus, offering improved efficacy through its prolonged half-life, which allows for less frequent dosing and better patient adherence when used in combination with antiviral medications such as ribavirin. For instance, in April 2025, according to the European Centre for Disease Prevention and Control (ECDC), a Europe-based agency for strengthening defenses against infectious diseases, in 2023, 28622 cases of hepatitis C were reported in 29 EU/EEA countries, corresponding to a crude rate of 7.4 cases per 100 000 population. Further, among the cases reported, 4.9% were acute, 34.1% chronic, and 53.8% were unknown. Therefore, the rising prevalence of hepatitis C is driving the growth of the pegintron industry. The increasing prevalence of chronic diseases is expected to fuel the growth of the pegintron market going forward. The increasing prevalence of chronic diseases is due to unhealthy lifestyles, poor dietary habits, lack of physical activity, environmental factors, and improved medical advancements that allow for better detection and longer life expectancy. Pegintron helps manage chronic diseases by stimulating the immune system to fight the virus, reducing viral load, and preventing long-term liver damage, making it a vital treatment option for patients with chronic viral infections who require sustained therapy to avoid complications such as cirrhosis and liver cancer. For instance, in September 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, there were 41 million deaths, which is 74% of those caused by non-communicable diseases (NCDs) or chronic diseases every year globally. There were 17.9 million deaths from cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths from chronic respiratory diseases, and 2.0 million deaths from diabetes. Therefore, the increasing prevalence of chronic diseases is driving the growth of the peginterferon market. The increasing biopharmaceuticals are expected to boost the growth of the pegintron market going forward. Biopharmaceuticals refer to medical drugs that are produced using biological processes rather than traditional chemical synthesis. The increasing demand for biopharmaceuticals is due to advancements in biotechnology, the rising prevalence of chronic diseases, and the growing need for targeted therapies that offer higher efficacy and fewer side effects compared to traditional medications. Biopharmaceuticals supports pengitron's capabilities by providing advanced therapeutic solutions, leveraging cutting-edge biotechnology to address complex medical challenges, improve patient outcomes, and drive innovation in healthcare delivery. For instance, in October 2025, according to the Office for Life Sciences, a UK-based government unit that drives growth and innovation in the life sciences sector, in 2023/2024, biopharmaceutical firms were far more R&D-focused, with 32% identifying research and development as their core activity, compared to just 10% of companies in the medical technology sector. Therefore, the increasing biopharmaceuticals are driving the growth of the pegintron industry.

Key Players In The Global Pegintron Market

Major companies operating in the pegintron market are Merck & Co. Inc.

Regional Insights

North America was the largest region in the pegintron market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Pegintron Market?

The pegintron market consists of sales of products including pegintron (peginterferon alfa-2b) and copegus (ribavirin). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pegintron Market Report 2026?

The pegintron market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pegintron industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.